Redondo M C, Arbo M D, Grindlinger J, Snydman D R
Department of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA.
Clin Infect Dis. 1995 Jun;20(6):1492-6. doi: 10.1093/clinids/20.6.1492.
Uncontrolled studies have suggested that Bacteroides fragilis group bacteremia has an attributable mortality rate between 13% and 33%. To determine the true attributable mortality rate and the mortality risk ratio associated with bacteremia due to the B. fragilis group, we conducted a matched-pair study in which cases were matched to controls for age, gender, year of admission, principal discharge diagnosis, and types of major surgery by an investigator blinded to survival status. Cases and controls were comparable in demographic and clinical characteristics. Cases had a significantly higher mortality rate (28% vs. 8.7%, P = .002, McNemar's test), with an attributable mortality rate of 19.3% (95% CI, 8%-30%; P = .003) and a mortality risk ratio of 3.2. In a multivariate analysis, three clinical factors were independently correlated with mortality: the presence of B. fragilis group bacteremia (RR: 4.9; 95% CI: 3.7-6.0; P = .009), congestive heart failure (RR: 8.0; 95% CI: 6.6-9.3; P = .003) or chronic liver disease (RR: 6.3; 95% CI: 4.8-7.7; P = .01). Cases also had a 16-day-longer stay in the hospital (P = .0007, Wilcoxon's signed rank test) compared with controls. Thus, B. fragilis group bacteremia contributes significantly to morbidity and mortality.
非对照研究表明,脆弱拟杆菌属菌血症的归因死亡率在13%至33%之间。为了确定与脆弱拟杆菌属菌血症相关的真正归因死亡率和死亡风险比,我们进行了一项配对研究,由一名对生存状况不知情的研究者将病例与对照在年龄、性别、入院年份、主要出院诊断和大手术类型方面进行匹配。病例和对照在人口统计学和临床特征方面具有可比性。病例的死亡率显著更高(28%对8.7%,P = .002,McNemar检验),归因死亡率为19.3%(95%CI,8%-30%;P = .003),死亡风险比为3.2。在多变量分析中,三个临床因素与死亡率独立相关:脆弱拟杆菌属菌血症的存在(RR:4.9;95%CI:3.7-6.0;P = .009)、充血性心力衰竭(RR:8.0;95%CI:6.6-9.3;P = .003)或慢性肝病(RR:6.3;95%CI:4.8-7.7;P = .01)。与对照相比,病例的住院时间也长16天(P = .0007,Wilcoxon符号秩检验)。因此,脆弱拟杆菌属菌血症对发病率和死亡率有显著影响。